INHIBITION OF CLASS I ANTIGEN PRESENTATION BY HSV ICP47

Project: Research project

StatusFinished
Effective start/end date3/1/963/31/09

Funding

  • National Institutes of Health: $372,400.00
  • National Institutes of Health: $412,900.00
  • National Institutes of Health: $469,203.00
  • National Institutes of Health
  • National Institutes of Health: $377,500.00
  • National Institutes of Health: $418,421.00
  • National Institutes of Health: $377,500.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $377,500.00
  • National Institutes of Health: $377,500.00
  • National Institutes of Health: $417,956.00
  • National Institutes of Health

Fingerprint

Cytomegalovirus
Histocompatibility Antigens Class II
Histocompatibility Antigens Class I
Simplexvirus
Cytomegalovirus Retinitis
Antigen Presentation
Viruses
T-Lymphocytes
Retinitis
Acquired Immunodeficiency Syndrome
HIV
Virus Diseases
Cellular Immunity
Proteins
Immune Evasion
Highly Active Antiretroviral Therapy
Bone Marrow
Antigens
Virus Latency
Quality of Life

ASJC

  • Medicine(all)